May 2025 exceptional surveillance of prostate cancer: diagnosis and management (NICE guideline NG131)
In May 2025, we reviewed this guideline in relation to the section on localised and locally advanced prostate cancer.
Surveillance decision
We will update the guideline around docetaxel and abiraterone for high-risk hormone-sensitive non-metastatic prostate cancer.
This page was last updated: